Connect with us

Hi, what are you looking for?

Oracle of  Omaha Says – Investing and Stock NewsOracle of  Omaha Says – Investing and Stock News


Eli Lilly Q2 results: its Alzheimer’s drug could be ‘the biggest drug in history’

Shares of Eli Lilly & Co (NYSE: LLY) are in the red this morning after the pharmaceutical giant reported weaker-than-expected results for its fiscal second quarter.

Key takeaways from Eli Lilly Q2 results

Net income printed at $952.5 million versus the year-ago $1.39 billion
Per-share earnings of $1.05 were well below last year’s $1.53
Adjusted EPS came in at $1.25, as per the earnings press release

Revenue slid 4.0% on a year-over-year basis to $6.488 billion
Consensus was $1.70 of adjusted EPS on $6.849 billion in revenue
Revenue from COVID-19 antibodies saw an annualised decline of 13%

Trulicity sales remained strong

The bright spot in Eli Lilly Q2 results was “Trulicity” that brought in $1.911 billion, up from $1.535 billion in the same quarter last year. In the earnings press release, CFO Anat Ashkenazi said:

Excluding revenue from Alimta loss of exclusivity in major markets, the sale of rights to Cialis in China in the base period, and COVID-19 antibodies, Lilly experienced 6% revenue growth in our core business.

Future outlook and Cramer’s remarks

Eli Lilly reiterated its guidance for $28.8 billion to $29.3 billion in revenue this year. It, however, expects to earn a lower $6.96 to $7.11 in fiscal 2022. In comparison, analysts had called for $7.68 of EPS on$29.126 billion in revenue.

“Foreign exchange” was a headwind for the NYSE-listed firm this quarter. Discussing Eli Lilly Q2 results on CNBC’s “Squawk on the Street”, Jim Cramer said:

The two things that matter to me are; the weight loss drug is off to a fast start. And the FDA wants to accelerate their Alzheimer’s drug. If the Alzheimer’s drug work, it will be the biggest drug in history.

Wall Street currently has a consensus “overweight” rating on Eli Lilly stock that’s up more than 10% (YTD) despite the ongoing bear market, thanks to the defensive nature of the “healthcare” space.

The post Eli Lilly Q2 results: its Alzheimer’s drug could be ‘the biggest drug in history’ appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Tele2 AB today announces a new partnership with security experts EBS to deliver a secure and managed IoT connectivity solution. Tele2 will support EBS...


    Anyone who has filled up the tank of their car this year will be aware of the rollercoaster ride that the price of oil...

    Latest News

    Sen. Patrick Leahy “was not feeling well” on Thursday and was admitted to the hospital overnight for observation, his office said in a statement....

    Latest News

    Joe Manchin is forcing Democrats into a brutal choice: Take a deal now to lower the costs of health care premiums and prescription drugs,...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023